Abstract: The present disclosure relates to compounds and methods which may be useful for modulating the expression of cnbp and treating diseases and conditions in which cnbp plays an active role.

Abstract: The present disclosure relates to compounds and methods which may be useful for modulating the expression of a target gene comprising a CGG trinucleotide repeat sequence and treating diseases and conditions in which the target gene plays an active role. The present disclosure provides compounds and methods for modulating the expression of fmr1 and fmr2, and provides compounds and methods for treating fragile X syndrome and fragile XE syndrome.

Abstract: The present disclosure relates to compounds and methods for modulating the expression of fxn, and treating diseases and conditions in which fxn plays an active role. The compound can be a transcription modulator molecule having a first terminus, a second terminus, and oligomeric backbone, wherein: a) the first terminus comprises a DNA-binding moiety capable of noncovalently binding to a trinucleotide repeat sequence GAA; b) the second terminus comprises a protein-binding moiety binding to a regulatory molecule that modulates an expression of a gene comprising the nucleotide repeat sequence GAA; and c) the oligomeric backbone comprising a linker between the first terminus and the second terminus.

Abstract: A pulsed xenon UV disinfection system for treating objects present inside a room and/or area surrounding the system. The system includes an head portion, an intermediate portion and a lower portion. The head portion includes a lamp, a housing and a reflector to redirect the UV rays in preferred direction. A shutter mechanism is disposed in the intermediate portion includes a shutter to provide protection to the lamp. A shape changing mechanism comprising second actuator to change shape of reflector as per the treatment conditions and/or physical characteristics of the room. The shape of reflector facilitates to converge or diverge UV rays emitted by the lamp to effectively treat objects/area close to the system or away from the system, respectively.

Abstract: A method may include receiving, by a computing system and from a first device, first data. The first data may be based at least in part on a first output from a first instance of a model processed by the first device. The method may further include receiving, by the computing system and from the first device, second data that was processed by the first instance of the model to produce the first output. The method may also include processing, by the computing system, the second data with at least a portion of a second instance of the model to produce a second output. The method may additionally include determining, by the computing system, third data based at least in part on the second output. Further, the method may include determining, by the computing system, that the third data is consistent with the first data.

Abstract: A new approach is proposed to support device under test (DUT) validation reuse across a plurality of platforms, e.g., hardware simulation, hardware emulation, and post-silicon validation. First, an inference profile used for an inference operation of an application, e.g., a machine learning (ML) application, is generated based on a set of profile configurations, a set of test parameters, and a set of randomized constraints. A plurality of math functions specified by, e.g., an architecture team, for the ML application are also statically and/or dynamically verified via block simulation and/or formal verification. An inference model for the DUT is then built based on the inference profile and the plurality of verified math functions. Finally, an inference database including one or more of stimulus, DUT configurations, input data and predicted output results is generated based on the inference model, wherein the inference database for the DUT is reusable across the plurality of platforms.

Abstract: The present disclosure relates to compounds and methods which may be useful for modulating the expression of fxn and treating diseases and conditions in which fxn plays an active role. The compound can be a transcription modulator molecule having a first terminus, a second terminus, and oligomeric backbone, wherein: a) the first terminus comprises a DNA-binding moiety capable of noncovalently binding to a nucleotide repeat sequence GAA; b) the second terminus comprises a protein-binding moiety binding to a regulatory molecule that modulates an expression of a gene comprising the nucleotide repeat sequence GAA; and c) the oligomeric backbone comprising a linker between the first terminus and the second terminus.

Abstract: The present disclosure relates to transcription modulator molecule compounds and methods for modulating the expression of dmpk, and treating diseases and conditions in which dmpk plays an active role. The transcription modulator comprising a) the first terminus comprising a DNA-binding moiety capable of noncovalently binding to a nucleotide repeat sequence CAG or CTG; b) a second terminus comprising a protein-binding moiety capable of binding to a regulatory molecule that modulates an expression of a gene comprising the nucleotide repeat sequence CAG or CTG; and c) an oligomeric backbone comprising a linker between the first terminus and the second terminus.

Abstract: The present disclosure relates to compounds and methods for modulating the expression of fxn, and treating diseases and conditions in which fxn plays an active role. The compound can be a transcription modulator molecule having a first terminus, a second terminus, and oligomeric backbone, wherein: a) the first terminus comprises a DNA-binding moiety capable of noncovalently binding to a trinucleotide repeat sequence GAA; b) the second terminus comprises a protein-binding moiety binding to a regulatory molecule that modulates an expression of a gene comprising the nucleotide repeat sequence GAA; and c) the oligomeric backbone comprising a linker between the first terminus and the second terminus.

Abstract: Drug products adapted for nasal delivery comprising formulations with epinephrine and devices comprising such formulations are provided. Methods of treating anaphylaxis with epinephrine products are also provided.

Abstract: The present disclosure relates to compounds and methods for modulating the expression of fxn, and treating diseases and conditions in which fxn plays an active role. The compound can be a transcription modulator molecule having a first terminus, a second terminus, and oligomeric backbone, wherein: a) the first terminus comprises a DNA-binding moiety capable of noncovalently binding to a nucleotide repeat sequence CGG; b) the second terminus comprises a protein-binding moiety binding to a regulatory molecule that modulates an expression of a gene comprising the nucleotide repeat sequence CGG; and c) the oligomeric backbone comprising a linker between the first terminus and the second terminus.

Abstract: Drug products adapted for nasal delivery comprising formulations with epinephrine and devices comprising such formulations are provided. Methods of treating anaphylaxis with epinephrine products are also provided.

Abstract: An example print material replenishment device includes a container to contain print material, a dispensing end to engage a fill port of a printing device, the dispensing end including an opening that is offset from a center axis of the container, and a rotatable cover coupled to the dispensing end, the rotatable cover to expose the opening of the dispensing end based on a rotation of the print material replenishment device.

Abstract: Drug products adapted for nasal delivery comprising formulations with epinephrine and devices comprising such formulations are provided. Methods of treating anaphylaxis with epinephrine products are also provided.

Abstract: The present disclosure relates to compounds and methods which may be useful for modulating the expression of a target gene comprising a CGG trinucleotide repeat sequence and treating diseases and conditions in which the target gene plays an active role. The present disclosure provides compounds and methods for modulating the expression of fmr1 and fmr2, and provides compounds and methods for treating fragile X syndrome and fragile XE syndrome.

Abstract: The present disclosure relates to compounds and methods for modulating the expression of bean (brain expressed, associated with NEDD4) and treating diseases and conditions in which bean plays an active role. The compound can be a transcription modulator molecule having a first terminus, a second terminus, and oligomeric backbone, wherein: a) the first terminus comprises a DNA-binding moiety capable of noncovalently binding to a nucleotide repeat sequence TGGAA; b) the second terminus comprises a protein-binding moiety binding to a regulatory molecule that modulates an expression of a gene comprising the nucleotide repeat sequence TGGAA; and c) the oligomeric backbone comprising a linker between the first terminus and the second terminus.

Abstract: Drug products adapted for nasal delivery comprising formulations with epinephrine and devices comprising such formulations are provided. Methods of treating anaphylaxis with epinephrine products are also provided.

Abstract: Drug products adapted for nasal delivery comprising formulations with epinephrine and devices comprising such formulations are provided. Methods of treating anaphylaxis with epinephrine products are also provided.

Abstract: The present disclosure relates to compounds and methods for modulating the expression of dmpk, and treating diseases and conditions in which dmpk plays an active role. The compound can be a transcription modulator molecule having a first terminus, a second terminus, and oligomeric backbone, wherein: a) the first terminus comprises a DNA-binding moiety capable of noncovalently binding to a nucleotide repeat sequence CAG or CTG; b) the second terminus comprises a protein-binding moiety binding to a regulatory molecule that modulates an expression of a gene comprising the nucleotide repeat sequence CAG or CTG; and c) the oligomeric backbone comprising a linker between the first terminus and the second terminus.

Abstract: Drug products adapted for nasal delivery comprising formulations with epinephrine and devices comprising such formulations are provided. Methods of treating anaphylaxis with epinephrine products are also provided.